About the Company
We do not have any company description for Calidi Biotherapeutics, Inc. at the moment.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) ('Calidi” or the 'Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and ...
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted ...
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to ...
Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public ...
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering April 16, 2024 08:31 AM Eastern Daylight Time ...
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
Detailed price information for Calidi Biotherapeutics Inc (CLDI-A) from The Globe and Mail including charting and trades.
Calidi Biotherapeutics Inc trading resumes
Biotherapeutics Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking ...
Calidi Biotherapeutics Granted U.S. Patent for Proprietary Therapeutic ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, has been ...
Calidi Biotherapeutics Inc. (NYSE American: CLDI ... - Morningstar
Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public ...
Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the pricing of its" reasonable best efforts" public ...
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision ...
Calidi Biotherapeutics Inc. is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease.
Similar Companies
Loading the latest forecasts...